登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式(希尔记法):
C19H18O2
化学文摘社编号:
分子量:
278.35
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D -43 to -35°, c = 0.5 in chloroform-d
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
C=C1C[C@@](CC2=CC3=C(C=C2)C=CC=C3)(C(OC4)=O)[C@]4([H])C1
InChI
1S/C19H18O2/c1-13-8-17-12-21-18(20)19(17,10-13)11-14-6-7-15-4-2-3-5-16(15)9-14/h2-7,9,17H,1,8,10-12H2/t17-,19+/m1/s1
InChI key
CVIRWLJKDBYYOG-MJGOQNOKSA-N
Biochem/physiol Actions
BAY36-7620 is a non-competitive, potent and selective metabotropic glutamate mGlu1 receptor (mGluR1) antagonist (IC50 = 160 nM against 0.1 μM (EC50) Glu-stimulated IP) with inverse agonist activity (IC50 = 380 nM with 36-44% basal IP inhibition at 10 μM). BAY36-7620 exhibits neuroprotective (0.01 and 0.03 mg/kg/h, iv. infusion during 4h post acute subdural hematoma induction in rats; triple 0.03-3 mg/kg bolus iv. 0, 2 & 4 h post middle cerebral artery occlusion in rats) and anticonvulsive (MED = 10 mg/kg, iv. immediately after pentylenetetrazole-induced convulsions in mice) efficacy in vivo.
Non-competitive, potent and selective metabotropic glutamate mGlu1 receptor (mGluR1) antagonist with neuroprotective and anticonvulsive efficacy in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
J De Vry et al.
European journal of pharmacology, 428(2), 203-214 (2001-10-25)
This study characterized the neuroprotective and behavioral effects of (3aS,6aS)-6a-naphtalen-2-ylmethyl-5-methyliden-hexahydro-cyclopenta[c]furan-1-on (BAY 36-7620), a novel, selective and systemically active metabotropic glutamate (mGlu)(1) receptor antagonist. In the rat, neuroprotective effects were obtained in the acute subdural hematoma model (efficacy of 40-50% at
Rachel E Sexton et al.
Scientific reports, 8(1), 16008-16008 (2018-10-31)
Breast cancer remains a major cause of death among women. 15% of these cancers are triple negative breast cancer (TNBC), an aggressive subtype of breast cancer for which no current effective targeted therapy exists. We have previously demonstrated a role
Paola Scandroglio et al.
Journal of biomolecular screening, 15(10), 1238-1247 (2010-09-03)
Recently, new technologies based on biosensors and called label free have been developed. These technologies eliminate the need for using markers and dyes. The authors applied one of these technologies, based on measurement of cell impedance variation, to study the
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML2917-25MG | 04061842701681 |
| SML2917-5MG | 04061842701698 |